Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I sent an email inquiry to Abattis asking for a link to GD Pharma. There are several companies with the name "GD Pharma" that come up during a web search but they seem unrelated to the South Korean company.
I'll post their response as soon as I get it.
And to the individual who posted that they had been to Korea twice last year and to different airports and didn't see anything regarding GD Pharma, let me just say that absence of evidence is not evidence of absence.
In my mail box today:
View this email in your browser
Abattis provides important update on Northern Vine and Sales Division
VANCOUVER, BRITISH COLUMBIA / September 13, 2017 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to provide an important update regarding its subsidiaries Northern Vine Canada Inc. (“Northern Vine”) and Vergence Naturals Ltd. (“Vergence”).
“We are very pleased with the continued progress being made to strengthen to the sales, marketing and distribution arm of Abattis and Northern Vine.” said Rob Abenante, President and CEO of Abattis. “We believe that the major value to be derived from the legal cannabinoid space will come from all downstream products and services derived from the cannabis plant. Vergence will be a direct gateway to sell products formulated at our labs in Northern Vine as well as others products which we are able to infuse with customized cannabinoid formulas. Abattis is equipped to service both of these rapidly evolving market’s and be fully prepared to be a market leader when recreational laws are passed.”
Website Launch and Online Retail Opportunity
Abattis is pleased to announce the official launch of the Vergence retail website, VergenceNaturals.com. The website is designed to streamline availability of the Vergence’s product lines, both developed in-house by Northern Vine and Abattis, as well as third-party products with which Vergence has distribution agreements. VergenceNaturals.com is a full-suite natural health products online store, through which all of Vergence’s products will eventually be featured and for sale.
“We’re very excited to launch VergenceNaturals.com, which should deliver not only sales revenue, but also important data on customer metrics for our carried lines,” said Mark Mansfield, VP of Sales at Vergence. “We see this sales portal as our Amazon, driving our goal is to be the go-to online retail location for natural health products. We look forward to the potential of incorporating Northern Vine’s CBD-infusion capabilities with not only the products we develop in-house, but with those we’ve signed distribution and marketing agreements with.”
Brands currently featured on the website include:
· Mogiana Coffee
· Jonny Hetherington
· Natrihealth
· Planet Hemp
· Beyond Silver
· Real Aloe
· Styrian Gold
· Maui Vera
In congruence with the launch of the website, Abattis is proud to announce the following sequence of distribution agreements signed by Vergence Naturals with high-quality third parties:
Distribution Agreement with Styrian Gold BC Inc.
Vergence has reached a global distribution agreement with Styrian Gold BC Inc., makers of the award-winning, 100% pure and unrefined Styrian Gold Pumpkin Seed Oil.
Styrian Gold Pumpkin Seed Oil delivers healthy antioxidants, vitamins and minerals vital for bodily functions. Consumption of the oil helps to aid the liver, bladder, urinary tract, and prostate, as well as having anti-inflammatory, anti-parasitic, and anti-diabetic benefits. Along with the oils, Styrian Gold also sells seeds and protein powder that it imports directly from an established and reputable oil pressing company in Styria.
Vergence will use its distribution and marketing channels to properly spread Styrian Gold products to global markets, and is proud to incorporate the line in its portfolio of products.
Distribution Agreement with Cascadia Soap Company
Vergence has reached a major North American distribution agreement with Cascadia Soap Company (or “Cascadia”), makers of natural skin care products under the same brand name.
Cascadia’s soaps, remedies, and infusions are made using classic artisan methods used for generations in the South of France. Along with all-natural ingredients such as rose hips, and dandelions to make the required salves and balms, Cascadia’s founder Joel Morassutti developed a technique to incorporate goat milk in the production of the company’s rich, long-lasting, and moisturizing cleansing bars. Goat milk is used to increase the health benefits of the milk’s liposomes in the soap.
Vergence has already listed the Cascadia Soaps best sellers on its new website, and is set to begin working on global distribution with partnered distributors.
Distribution Agreement with Naturally Canadian Foods
Vergence has signed a global distribution deal with Naturally Canadian Superfoods Inc., direct importers, distributors, and brokers of several products including Realoe, Maui Vera, and the hemp superfood line Planet Hemp.
“Key to the deal is the potential to co-develop products with Naturally Canadian Superfoods’, through our subsidiary, Northern Vine,” said Rob Abenante, President and CEO of Abattis. “We believe there is major potential for synergistic product lines still-to-be develop between Northern Vine and our new partners, through enhancement of formulas with the medical benefits of CBD oils.”
Naturally Canadian Superfoods’s product lines include natural and organic aloe vera sun care and lotion product lines Realaloe and Maui Vera, as well as hemp superfood line Planet Hemp, a natural buckwheat seaweed product line, a spice line from India, and an organic garden hose line, among other products.
Distribution Agreement with Smartpep Canada Biological Tech (DBA Natrihealth)
Vergence has signed a global distribution agreement with Smartpep Canada Biological Tech (DBA) Natrihealth (or “Smartpep”), for the “Natrihealth” brand of collagen supplements. Smartpep brings with it previously forged partnerships in North America, Asia, Japan, Korea, and Hong Kong among its markets, and boasts only the best, high-quality ingredients in its products.
The “Natrihealth” brand produces several collagen supplements, utilizing tripeptide technology. Unlike most collagen supplements on the market which are mass produced cheaply using beef and poultry, Natrihealth has focused on a higher quality fish-based formula.
“We are adding new brands to the website every week”, adds Andrea Bates, COO of Vergence Naturals, “…and we are very excited about the development of our own high end Vergence product lines. For example, we are currently working on a line of premium wild BC honeys, a luxury all natural, organic plant based cosmetic line and a CBD sunscreen which is being developed by our lab, Northern Vines.”
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.
About Vergence Naturals Ltd.
Vergence Naturals TM is a wholly owned subsidiary of Abattis, based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.
About Northern Vine Canada Inc.
Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP.
“Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com
For inquiries, please contact the Company at (604) 336-0881 or at news@abattis.com.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the expected volume of sales of the Johnny Hetherington Hot Sauce and Ketchup products through distribution channels in Asia and North America; the build-up of retail presence nationally and internationally over time; the standards and quality of Vergence products; the addressing of health and dietary concerns; the suitability of the products for a healthy lifestyle; the ingredients in the products; the quality and safety of the products; and, the shelf life of the products. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including that the Johnny Hetherington products or other products sold via Abattis or Vergence may not sell as expected or at all, the Company may be unsuccessful in developing new product formulations in the time expected or at all, the Company may not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues, the Company’s competitors may develop competing technologies (such competitors may also have greater financial resources and are able to affect their business plan more rapidly), changes in regulatory requirements and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where as a result of new information, future events or results, or otherwise, except as required by applicable securities laws.
Copyright © 2017 Abattis Bioceuticals Corp., All rights reserved.
Our mailing address is:
#224 - 970 Burrard St., Vancouver, BC V6K 2Z4
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
This email was sent to mchinard@gmail.com
why did I get this? unsubscribe from this list update subscription preferences
Abattis Bioceuticals Corporation · 224 - 970 Burrard St. · Vancouver, BC V6K 2Z4 · Canada
Email Marketing Powered by MailChimp
FYI - just received link in an email. PR but interesting never-the-less.
http://stocksyndicate.com/blog/powering-cannabis-industry-abattis-att-c-attbf/?utm_source=Dissemination+List+-+Abattis&utm_campaign=00c9f73f03-EMAIL_CAMPAIGN_2017_08_30&utm_medium=email&utm_term=0_2432235186-00c9f73f03-265637841
Let me repeat my post from a few days ago where I copied and pasted an email I received from Abattis:
"Abattis remains a shareholder in Experion. Abattis is not active in the management of Experion's business.
Kathleen Martin"
So unequivocally Abattis is a shareholder in Experion. I sent an email to them and received a response in less than an hour. When we don't know something it is best to go to the source and just ask instead of speculating negatively for positively.
I don't mind stock speculation - that's how I've made a little money over the years by buying low and selling high. I do mind the other speculation which is just speculative opinion stated as "fact".
I try to limit my postings on this board to just forwarding information which I think is useful for other board members and investors. I don't attach an opinion or interpretation - I'm not qualified to do so.
Regards
Just received this email in response to my inquiry:
"Abattis remains a shareholder in Experion. Abattis is not active in the management of Experion's business.
Kathleen Martin"
Just sent an email inquiry to Abattis regarding the status of the relationship with Expereion. I will post their reply as soon as I hear back from them.
Regards
You maybe right. Only Vergence and Northern Vine are listed in their "portfolio"
on the Abattis website.
Why Experion is not mentioned on the Abattis website is open to conjecture.
This what is mentioned of Experion in the latest financial report. But the report is only current to March 31st, 2017
"8.
On April 10, 2014, the Company through its wholly-owned subsidiary, Northern Vine, entered into a share exchange agreement with Experion Biotechnologies Inc. (“Experion”), a company incorporated under the laws of British Columbia, Canada. Pursuant to the terms of the agreement, Experion and Northern Vine have exchanged 25% of each parties’ issued and outstanding common shares. The Company maintains a 75% ownership in Northern Vine."
Regards
Today's email:
Abattis Partners With The CSE & Stockpools
Vancouver, BC – July 13, 2017 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT) has partnered with the Canadian Securities Exchange (“CSE”), Stockpools and Lift Cannabis Expo to educate market players on the cannabis industry through an innovative fantasy online stock trading competition focused entirely on the cannabis sector titled, “The 2017 Cannabis Investment Challenge”.
Abattis is the title sponsor for this competition which is also 100% free and available to anyone over the legal age of consent. The competition began on July 4th, 2017 and will run through to September 15th, 2017. Prizes include weekly cash draws, as well as a grand prize of a trip to Las Vegas for the best performing portfolio.
Abattis is positioned competitively as a natural hedge against most of publicly traded cannabis picks in the cultivation space. With the goal of providing downstream fulfillment and processing services to the legal cannabis industry, the Company will see the market for its services open up as Health Canada’s move to facilitate new licences intensifies the competition. Recent activity in the capital markets suggest that many Licensed Producers (“LPs”) have struggled to ramp production and have therefore missed consensus expectations for sales volumes. In addition, the capital markets have come back from the highs of April and settled at a more sustainable level before the upcoming fall season.
Jason Zandberg, Analyst at PI Financial is quoted in the June 7th 2017 Globe & Mail saying: “All marijuana companies rose during the ‘pot mania’. Accumulating shares of market leaders as prices fall may prove to be a profitable trade”.
Abattis has maintained its focus with its primary subsidiary, Northern Vine Labs, offering testing, extraction and formulation services to licensed producer and ACMPR license holders. Northern Vine is currently taking samples, generating revenues and refining its methods and standards to ensure the utmost in accuracy, consistency and safety. Additionally, the company’s sales and marketing subsidiary, Vergence Naturals, has been busy securing distribution agreements with third party natural health products for placement in local and international sales channels.
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.
About Northern Vine Canada Inc.
Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.
About Vergence Visionary Bioceuticals Corp.
Vergence Visionary Bioceuticals Corp., dba Vergence NaturalsTM, is a wholly owned subsidiary of Abattis, based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,
“Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com
For inquiries, please contact the Company at (604) 336-0881 or at news@abattis.com.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding Abattis’ position as a natural hedge against most of the publicly traded companies in the cannabis space; the production volume of LPs, the performance of the LPs and the capital markets in general; expected volume of services to be provided at the Northern Vine lab; the goal of providing downstream fulfillment and processing services to the legal cannabis industry; the future size of the market for the services of Northern Vine; the competitive landscape of the testing, cultivation, extraction and formulation industry; the impact of Health Canada issuing more testing licences; the, accuracy, consistency and safety of the testing; the ability to secure distribution agreements with third part producers for placement in national and international sales channels; the ability to acquire intellectual property rights to agricultural technologies; and, the continued generation of revenues through its testing, formulation, extraction and sales of natural health products. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including that the testing and formulation and extraction technologies may not work as expected or at all, the Company will be unsuccessful in developing new product formulations in the time expected or at all, the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues, the Company’s competitors may develop competing technologies, changes in regulatory requirements and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where as a result of new information, future events or results, or otherwise, except as required by applicable securities laws.
Copyright © 2017 Abattis Bioceuticals Corporation, All rights reserved.
You are receiving this email because you are on our mailing list.
Our mailing address is:
Abattis Bioceuticals Corporation
224 - 970 Burrard St.
Vancouver, BC V6K 2Z4
Canada
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list
Email Marketing Powered by MailChimp
Just received this email:
Abattis Provides Company Update
Vancouver, BC – June 13, 2017 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT) (OTCQB: ATTBF) is pleased to provide an update of recent developments and achievements.
Testing Revenues at Northern Vine LabsTM
Since the launch of its first lab in May of 2017, the Company’s subsidiary, Northern Vine Canada Inc. (“Northern Vine”), has been successfully accepting cannabis flower, oil and edible samples at its lab in Langley, BC. The team of scientists continues to perfect their methods and are successfully issuing Certificates of Analysis (“COA’s”) to early lab clientele.
Capacity Expansion at Northern Vine LabsTM
Due to demand for testing at Northern Vine LabsTM, the Company has commenced the process of enhancing its security to Level 6 to increase the amount of controlled substances it can hold and process in the lab. This will enable Northern Vine to significantly increase the volume of services it can provide to licensed producers and ACMPR patients.
Extraction Technology
On April 20, 2017, Abattis signed an exclusive distribution agreement with Suzhou Raybot Material Tech Corp. (“Raybot”). The agreement allows Abattis to use Raybot’s proprietary extraction technology and to exclusively sell the extraction equipment and services. The Company has now received one of Raybot’s extraction machines at its Northern Vine lab and has commenced testing of the machinery. The results of the testing will be disclosed once testing is complete.
“We are very excited and eagerly await the results of this technology,” stated Abattis President & CEO, Robert Abenante. “This technology has the potential to significantly disrupt the cannabinoid extraction process. With a growing supply chain and increasing consumer demand for derivative products, being able to cost effectively extract cannabinoids at an industrial scale will allow us to have a significant competitive advantage over competing extraction technologies.”
Formulations at Northern Vine LabsTM
The team of scientists at Northern Vine, led by Dr. David Galvez, have begun formulation efforts on a proprietary cannabinoid infused product for strategic marketing, with intended distribution as early as fall of 2017. The team has identified an array of unique ingredients and delivery methods for maximum bioavailability and product efficacy and has begun brand development and marketing efforts around this initiative.
Distribution at Vergence NaturalsTM
The relaunch of the Company’s Sales and Marketing subsidiary, Vergence Visionary Bioceuticals (“Vergence”), is well underway. The Company has been evaluating and performing due diligence on several products to distribute through its established channels. Vergence will also be the exclusive distribution channel for proprietary products it intends to formulate at Northern Vine LabsTM.
Education and Awareness
The Sales and Marketing team at Northern Vine has begun the implementation of a series of outreach initiatives to further its educational #knowyourmedicine campaign. Once live, the campaign will reach audiences through several mediums, including social media and print magazines. The Company remains committed to bringing awareness to the masses in this rapidly developing industry.
Management Additions
With the increased activity in its primary divisions, the Company has been working to add key positions to its management team in order to support the Company’s aggressive growth targets. Key appointments will be announced once finalized in the coming weeks.
“I am very excited by the Company’s rapid growth and pleased by the high level of talent the Company has been able to attract,” said Mr. Abenante. “I believe we are well positioned and have the right people in place for continued growth of the Company.”
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.
About Northern Vine Canada Inc.
Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.
About Vergence Visionary Bioceuticals Corp.
Vergence, dba Vergence NaturalsTM, is a wholly owned subsidiary of Abattis, based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast growing market for natural, safe and effective natural products that meet unmet wellness needs.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,
“Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com
For inquiries, please contact the Company at (604) 336-0881 or at news@abattis.com.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the expected volume of services to be provided at the Northern Vine lab, the timing of results of testing of the Raybot machine, that the Raybot technology has the potential to significantly disrupt the cannabinoid extraction process and will allow the Company to have a significantly competitive advantage over competing extraction technologies, the timing of product initiatives to be formulated at Northern Vine lab, the expected reach of the Company’s #knowyourmedicine campaign, the Company’s short and long-term growth plans, the Company’s goal to become one of the premier companies in the cannabis sector, and the Company’s plan to acquire exclusive intellectual property rights to agricultural technologies. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including that the Raybot technology may not work as expected or at all, the Company will be unsuccessful in developing new product formulations in the time expected or at all, the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues, the Company’s competitors may develop competing technologies, changes in regulatory requirements and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where as a result of new information, future events or results, or otherwise, except as required by applicable securities laws.
Copyright © 2017 Abattis Bioceuticals Corporation, All rights reserved.
You are receiving this email because you are on our mailing list.
Our mailing address is:
Abattis Bioceuticals Corporation
224 - 970 Burrard St.
Vancouver, BC V6K 2Z4
Canada
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list
Email Marketing Powered by MailChimp
IIROC Trade Resumption - ATT
Canada NewsWire
TORONTO, April 10, 2017
TORONTO, April 10, 2017 /CNW/ - Trading resumes in:
Company: Abattis Bioceuticals Corp.
CSE Symbol: ATT
Resumption (ET): 11:00 AM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
View original content: http://www.newswire.ca/en/releases/archive/April2017/10/c6845.html
IIROC Inquiries 1-877-442-4322 (Option 2) - Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.Copyright CNW Group 2017
News Provided by QuoteMedia.
"U1 Trading Halt - Foreign Regulatory Halt. Trading is halted because the OTC Equity Issue or the issue underlying an American Depository Receipt ("ADR") that is an OTC Equity issue ("OTC ADR") is listed on or registered with a foreign issues exchange or market, and the foreign issues exchange, market, or regulatory authority overseeing such issuer, exchange, or market, has halted trading in such issue for regulatory reasons because of public interest concerns or for news pending."
http://otce.finra.org/TradeHaltsCurrent
This just showed up on my Facebook feed. Sorry the copy and paste only includes the text and link but not the graphics
Abattis Bioceuticals
1 hr ·
We're ready. Coffee time.
https://www.northernvinelabs.com/blog
Image may contain: one or more people and closeup
LikeShow more reactionsCommentShare
This just showed up on my Facebook feed
Abattis Bioceuticals
1 hr ·
We're ready. Coffee time.
https://www.northernvinelabs.com/blog
Image may contain: one or more people and closeup
LikeShow more reactionsCommentShare
Not Goldman Sachs but Goldman Small Cap Research. No relation other than a shared name.
Press release from Abatitis received today
Licensed Producer Class Action Lawsuit Highlights Need For Testing
Vancouver, BC –, 2017 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), is continuing to prepare its subsidiary, Northern Vine Canada Inc., Health Canada licensed testing facility for operations as the licensed producer industry is confronted with legal actions relating to cultivation practices. Two federally regulated medical-marijuana producers are now facing proposed class-action lawsuits from patients who unknowingly ingested banned pesticides, according to a recent Globe and Mail article.
http://www.theglobeandmail.com/news/national/mettrum-organigram-medical-marijuana-proposed-class-action-lawsuits/article34216937/
“Mettrum Ltd. and OrganiGram Inc. were both found selling medical marijuana that contained unauthorized chemicals, including the controversial pesticide myclobutanil, which produces hydrogen cyanide when combusted and can lead to serious health problems.”
Both companies have recently gone through product recalls. Health Canada has once again been called into question for a lack of oversight and testing requirements on “medical” products offered by the federally regulated licensed producers. Health Canada now says it will be conducting random testing of medical cannabis goods made by licensed producers in an effort to combat tainted products and to ensure consumer confidence in Canada’s nascent yet burgeoning cannabis industry.
Northern Vine’s management strongly believes the whole market will benefit from increased testing and safer consumption of cannabis. With this in mind, Northern Vine is preparing for a social media campaign, titled #knowyourbud in an effort to spread awareness on the need for product testing and safe consumption. This push towards overall market safety should give the general public some added assurance if and when Canada imposes its new legislative and regulatory framework for legal access to cannabis.
At the same time, Abattis, the parent company of Northern Vine, has begun to realize revenues through its wholly owned subsidiary, Vergence Bioceuticals. The company has been selling Green Nature branded products into China and looks to expand the market for these natural health products through a string of trade shows and sales meetings in 2017. Abattis plans to leverage these international distribution networks as it looks to add licensed products to the Vergence portfolio along with in-house branded formulations for end consumption.
About Abattis Bioceuticals Corp.
Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company also is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
About Northern Vine Canada Inc.
Northern Vine Labs™ is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purposes of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the Canadian market.
About Vergence Visionary Bioceuticals Corp.
Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis Bioceuticals Corp. based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.
About Green Nature Health Care Products
Green Nature Health Care Products Inc. (http://www.green-nature.ca/en/) was established in 2012 by Jasmine Guan. The main market is the local travelers and immigrants, wholesalers. Over 400 customers have been obtained in China since the end of 2012 on dried blueberry and cranberry dried products, including the Wal-Mart chain supermarket and more than 200 to import and export food-based industry chain supermarkets. Green Nature has customs clearance through six cities in China: Shanghai, Nantong, Qingdao, Tianjin, Guangzhou, Hong Kong.
ON BEHALF OF THE BOARD
"Rene David"
Rene David, CFO, Acting CEO
For further information, contact the Company at (604) 336-0881 or at news@abattis.com.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Copyright © 2014 Abattis Bioceuticals Corp, All rights reserved.
Our mailing address is:
Suite 104 - 9295 198th St.
Langley, BC Canada V7M 3J9